Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 08, 2024, titled "Zydus receives Final Approvals from the USFDA for Dexamethasone Tablets USP, 0.5 mg, 0.75 mg, 1.5 mg, 4 mg and 6 mg and Dexamethasone Tablets USP, 2 mg".
Press Release Feb 08 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding final approvals from the USFDA for various strengths of Dexamethasone Tablets. The approvals allow Zydus to manufacture and market these tablets, which are used to treat several medical conditions. The products will be produced at the company's facility in Baddi, Himachal Pradesh.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Press Release Jan 30 2024
- Press Release Jan 25 2024
- Press Release Jan 19 2024
- Press Release Jan 17 2024
- Press Release Dec 22 2023
Later from Zydus Lifesciences
- Press Release Feb 09 2024
- Press Release Feb 16 2024
- Zydus Lifesciences Limited Press Release Feb 26 2024
- Press Release Mar 13 2024
- Press Release Mar 14 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences